Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/EXELIXIS-INC-9235/news/Exelixis-Announces-Detailed-Results-of-Phase-3-CONTACT-02-Pivotal-Trial-Evaluating-Cabozantinib-in-C-45812738/?utm_source=whatsapp&utm_medium=social&utm_campaign=share